Lupin (LUPIN) — Announcement

1 Announcement 🔴 High Importance Neutral 📄 PDF

Lupin Limited filed a general corporate disclosure on the NSE on June 25, 2025, reaffirming its operational continuity and regulatory compliance without disclosing new financial results or strategic initiatives. The filing underscores routine governance updates for investors tracking the company's market presence.

2 Announcement ✨ Positive 📄 PDF

Lupin announced that the U.S. FDA approved its Abbreviated New Drug Application for Prucalopride Tablets, 1 mg and 2 mg, bioequivalent to Takeda’s Motegrity® for chronic idiopathic constipation. The product will be manufactured at Lupin’s Goa facility and targets a $184 million U.S. market opportunity.

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How does this announcement affect Lupin Limited's outlook?" "What did Lupin Limited announce on 25 June 2025?" "Is this positive or negative for LUPIN?"

Ask AI Free →

📊 More LUPIN filings

See all LUPIN filings →

🔥 Also filed on 25 June 2025

RELIANCE Reliance Industries Limited Corporate Action SHRIRAMFIN Shriram Finance Limited Annual Report SUNPHARMA Sun Pharmaceutical Industries Limited Announcement SBIN State Bank of India Insider Trading TATASTEEL Tata Steel Limited Announcement UNIONBANK Union Bank of India Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.